XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released updated information regarding its drug formulation and development focus. The company is continuing its focus on advancing multiple generic and hybrid-generic programs for neurotherapeutics. Highlights of the update include that planning for XPhyto’s Rotigotine transdermal skin patch optimization and pivotal study has begun with manufacturing, sales and marketing preparation of the Rotigotine patch beginning. In addition, XPHYF’s cannabinoid oral dissolvable film (“ODF”) programs have moved forward and are ready for a pilot study. The company is also prioritizing additional near-term drug formulation programs. The company’s drug-formulation business remains focused on scalable, low-cost development opportunities for generic and hybrid-generic drug products; XPhyto is specifically evaluating those with expedited pathways to regulatory approval, with particular interest in transdermal and oral dissolvable opportunities. The company is also focused on its psychedelic medicine program and anticipates making key announcements regarding its API production and drug formulation moving forward. “XPhyto’s strategy is to advance its thin-film technology platform to develop innovative formulations of generic and hybrid-generic drugs,” said XPhyto CEO and director Hugh Rogers in the press release. “In 2021, we have completed the pilot study for our lead program and are expecting to complete pilot studies for our three cannabinoid drug formulation programs in Q4 2021 and Q1 2022. We are also looking to expand our near-term product pipeline beyond neurotherapeutics and are expecting considerable synergies with other XPhyto business lines by applying our drug delivery expertise to psychedelic compounds and to delivering biosensors via our proprietary oral dissolvable platform.”
To view the full article, visit
https://ibn.fm/xfRmf
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany. The company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit
www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at
https://ibn.fm/XPHYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.